| Original language | English (US) |
|---|---|
| Pages (from-to) | e130-e133 |
| Journal | Journal of the European Academy of Dermatology and Venereology |
| Volume | 35 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2021 |
ASJC Scopus subject areas
- Dermatology
- Infectious Diseases
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis : results from five randomized clinical trials. / Beck, L. A.; Silverberg, J. I.; Simpson, E. L.; Yosipovitch, G.; Eckert, L.; Guillemin, I.; Chen, Z.; Ardeleanu, M.; Plaum, S.; Graham, N.; Ruddy, M.; Pirozzi, G.; Gadkari, A.
In: Journal of the European Academy of Dermatology and Venereology, Vol. 35, No. 2, 02.2021, p. e130-e133.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis
T2 - results from five randomized clinical trials
AU - Beck, L. A.
AU - Silverberg, J. I.
AU - Simpson, E. L.
AU - Yosipovitch, G.
AU - Eckert, L.
AU - Guillemin, I.
AU - Chen, Z.
AU - Ardeleanu, M.
AU - Plaum, S.
AU - Graham, N.
AU - Ruddy, M.
AU - Pirozzi, G.
AU - Gadkari, A.
N1 - Funding Information: L. Beck is a consultant for AbbVie, Allakos, Arena Pharma, AstraZeneca, Connect Biopharma, Leo Pharma, Lilly, Novan, Novartis, Pfizer, Regeneron, Sanofi, UCB and Vimalan and an investigator for AbbVie, Leo Pharma, Pfizer and Regeneron and owns stock in Pfizer and Medtronics. G. Yosipovitch has received research funding from Leo, Sun Pharma, Kiniksa, Pfizer, Sanofi Regeneron and Vanda, and is a consultant for and advisory board member of Sanofi Regeneron, Pfizer, Eli Lilly, Novartis, Menlo Therapeutics, Trevi, Sienna, AbbVie, Bayer, Ortho and Kiniksa. E.L. Simpson has received grant/research support from AbbVie, Eli Lilly Co., Galderma, Kyowa Hakko Kirin, Leo Pharmaceutical Co., Merck, Pfizer and Regeneron Pharmaceuticals, Inc., and consulting fees from AbbVie Inc., Boehringer Ingelheim, Dermavant, Eli Lilly Co., Forte Bio, Incyte, Leo Pharmaceutical Co., Menlo Therapeutics, Pfizer, Pierre Fabre Dermo Cosmetique, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme and Valeant. J.I. Silverberg has acted as a consultant for, and/or received grants/honoraria from, AbbVie, AnaptysBio, Asana Biosciences, LLC, Eli Lilly and Company, Galderma Research & Development, LLC, GlaxoSmithKline, Glenmark Generics Inc., Kiniksa Pharmaceuticals, Ltd., Leo Pharma Inc., Medimmune, Menlo Therapeutics, Pfizer Inc., PuriCore, Inc., Regeneron Pharmaceuticals, Inc., and Sanofi. Eckert L, Plaum S and Guillemin I are employees of and stockholders in Sanofi. Pirozzi G was an employee of Sanofi at the time of the study and is currently a full‐time employee of Alexion Pharmaceuticals, Inc. Chen Z, Ardeleanu M and Graham N employees of and stockholders in Regeneron Pharmaceuticals, Inc. Gadkari A was an employee of Regeneron Pharmaceuticals, Inc., at the time of the study, and is currently a full‐time employee of Boehringer Ingelheim. Funding Information: This study was financially supported by Regeneron Pharmaceuticals, Inc., and Sanofi. Funding Information: This study was financially supported by Regeneron Pharmaceuticals, Inc., and Sanofi. L. Beck is a consultant for AbbVie, Allakos, Arena Pharma, AstraZeneca, Connect Biopharma, Leo Pharma, Lilly, Novan, Novartis, Pfizer, Regeneron, Sanofi, UCB and Vimalan and an investigator for AbbVie, Leo Pharma, Pfizer and Regeneron and owns stock in Pfizer and Medtronics. G. Yosipovitch has received research funding from Leo, Sun Pharma, Kiniksa, Pfizer, Sanofi Regeneron and Vanda, and is a consultant for and advisory board member of Sanofi Regeneron, Pfizer, Eli Lilly, Novartis, Menlo Therapeutics, Trevi, Sienna, AbbVie, Bayer, Ortho and Kiniksa. E.L. Simpson has received grant/research support from AbbVie, Eli Lilly Co., Galderma, Kyowa Hakko Kirin, Leo Pharmaceutical Co., Merck, Pfizer and Regeneron Pharmaceuticals, Inc., and consulting fees from AbbVie Inc., Boehringer Ingelheim, Dermavant, Eli Lilly Co., Forte Bio, Incyte, Leo Pharmaceutical Co., Menlo Therapeutics, Pfizer, Pierre Fabre Dermo Cosmetique, Regeneron Pharmaceuticals, Inc., Sanofi Genzyme and Valeant. J.I. Silverberg has acted as a consultant for, and/or received grants/honoraria from, AbbVie, AnaptysBio, Asana Biosciences, LLC, Eli Lilly and Company, Galderma Research & Development, LLC, GlaxoSmithKline, Glenmark Generics Inc., Kiniksa Pharmaceuticals, Ltd., Leo Pharma Inc., Medimmune, Menlo Therapeutics, Pfizer Inc., PuriCore, Inc., Regeneron Pharmaceuticals, Inc., and Sanofi. Eckert L, Plaum S and Guillemin I are employees of and stockholders in Sanofi. Pirozzi G was an employee of Sanofi at the time of the study and is currently a full-time employee of Alexion Pharmaceuticals, Inc. Chen Z, Ardeleanu M and Graham N employees of and stockholders in Regeneron Pharmaceuticals, Inc. Gadkari A was an employee of Regeneron Pharmaceuticals, Inc., at the time of the study, and is currently a full-time employee of Boehringer Ingelheim.
PY - 2021/2
Y1 - 2021/2
UR - http://www.scopus.com/inward/record.url?scp=85090302168&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090302168&partnerID=8YFLogxK
U2 - 10.1111/jdv.16865
DO - 10.1111/jdv.16865
M3 - Letter
C2 - 32789996
AN - SCOPUS:85090302168
VL - 35
SP - e130-e133
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
SN - 0926-9959
IS - 2
ER -